These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 23696264)
1. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W; Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264 [TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492 [TBL] [Abstract][Full Text] [Related]
3. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. Kamei H; Ito Y; Kawada J; Ogiso S; Onishi Y; Komagome M; Kurata N; Ogura Y Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384 [TBL] [Abstract][Full Text] [Related]
4. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation. Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881 [TBL] [Abstract][Full Text] [Related]
5. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884 [TBL] [Abstract][Full Text] [Related]
6. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308 [TBL] [Abstract][Full Text] [Related]
7. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children. Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323 [TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults. Ruijter BN; Tushuizen ME; van der Helm D; Hew M; Reeven M; Vossen ACTM; Metselaar HJ; Alwayn IPJ; Dubbeld J; Polak WG; van Hoek B Liver Transpl; 2024 Jun; 30(6):640-646. PubMed ID: 37698933 [TBL] [Abstract][Full Text] [Related]
9. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation. Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation. Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718 [TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center. Dogan B; Sema YA; Bora K; Veysel U; Benan D; Ezgi KT; Gozde AK; Demir D; Ozsan N; Hekimgil M; Zumrut SB; Miray K; Funda C; Sema A J Med Virol; 2024 Jun; 96(6):e29767. PubMed ID: 38932460 [TBL] [Abstract][Full Text] [Related]
12. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761 [TBL] [Abstract][Full Text] [Related]
13. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation : A Cohort Study. Ruijter BN; Wolterbeek R; Hew M; van Reeven M; van der Helm D; Dubbeld J; Tushuizen ME; Metselaar H; Vossen ACTM; van Hoek B Ann Intern Med; 2023 Feb; 176(2):174-181. PubMed ID: 36645888 [TBL] [Abstract][Full Text] [Related]
15. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy. Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021 [TBL] [Abstract][Full Text] [Related]
16. Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation. Hayes D; Breuer CK; Horwitz EM; Yates AR; Tobias JD; Shinoka T Pediatr Cardiol; 2015 Dec; 36(8):1748-53. PubMed ID: 26187515 [TBL] [Abstract][Full Text] [Related]
17. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. Chinnock R; Webber SA; Dipchand AI; Brown RN; George JF; Am J Transplant; 2012 Nov; 12(11):3061-8. PubMed ID: 23072522 [TBL] [Abstract][Full Text] [Related]
18. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761 [TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States. Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750 [TBL] [Abstract][Full Text] [Related]
20. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]